Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    D8540C00002
Previous Study | Return to List | Next Study

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03811652
Recruitment Status : Recruiting
First Posted : January 21, 2019
Last Update Posted : April 12, 2019
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC

Brief Summary:
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Squamous (NSCLC-Sq) Head and Neck Squamous Cell Carcinoma (HNSCC) Small Cell Lung Cancer (SCLC) Pancreatic Ductal Adenocarcinoma (PDAC) Colorectal Cancer (CRC) Metastatic Castration-resistant Prostate Cancer (mCRPC) Drug: MEDI7247 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 336 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
Actual Study Start Date : December 20, 2018
Estimated Primary Completion Date : March 3, 2022
Estimated Study Completion Date : March 3, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NSCLC-Sq/HNSCC
Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Experimental: Small Cell Lung Cancer
Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Experimental: Colorectal Cancer
Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Experimental: Pancreatic Ductal Adenocarcinoma
Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Experimental: Metastatic Castration-Resistant Prostate Cancer
Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule

Experimental: Other advanced/metastatic target expressing solid tumors
Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
Drug: MEDI7247
Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule




Primary Outcome Measures :
  1. Occurrence of Adverse Events [ Time Frame: From time of informed consent through 90 days post end of treatment ]
    To assess the occurrence of adverse events

  2. Occurrence of Serious Adverse Events [ Time Frame: From time of informed consent through 90 days post end of treatment ]
    To assess the occurrence of serious adverse events

  3. Occurrence of Dose Limiting Toxicities [ Time Frame: During the evaluation period of 21 days post first dose ]
    To assess the occurrence of toxicities and abnormal laboratory results that may limit further dose administration

  4. Number of patients with changes in laboratory parameters from baseline [ Time Frame: From time of informed consent through 90 days post end of treatment ]
    To assess serum chemistry, hematology, urinalysis and coagulation parameters

  5. Number of patients with changes in vital signs parameters from baseline [ Time Frame: from time of informed consent through 21 days post last dose ]
    to assess changes in vital signs

  6. Number of patients with changes in electrocardiogram results from baseline [ Time Frame: from time of informed consent through 21 days post last dose ]
    to assess changes in ECG

  7. Percentage of patients with changes in laboratory parameters from baseline [ Time Frame: from time of informed consent through 90 days post end of treatment ]
    to assess changes in serum chemistry, hematology, urinalysis, and coagulation parameters


Secondary Outcome Measures :
  1. MEDI7247 maximum observed concentration (Cmax) [ Time Frame: From first dose through 90 days post end of treatment ]
    To characterize MEDI7247 single agent Pharmacokinetics

  2. MEDI7247 terminal half life (t1/2) [ Time Frame: From first dose through 90 days post end of treatment ]
    To characterize single agent MEDI7247 pharmacokinetics

  3. MEDI7247 area under the concentration/time curve (AUC) [ Time Frame: from first dose through 90 days post end of treatment ]
    To characterize single agent MEDI7247 pharmacokinetics

  4. MEDI7247 clearance [ Time Frame: from first dose through 90 days post end of treatment ]
    to characterize the single agent MEDI7247 pharmacokinetics

  5. Number of subjects who develop anti-drug antibodies [ Time Frame: first dose through 90 days post end of treatment ]
    To characterize MEDI7247 immunogenicity

  6. Best Overall Response [ Time Frame: From time of informed consent and up to 90 days post end of treatment ]
    To assess antitumor activity of MEDI7247

  7. Objective Response Rate (ORR) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247

  8. Time to Response (TTR) [ Time Frame: From time of informed consent and up to 90 days post end of treatment ]
    To assess antitumor activity of MEDI7247

  9. Duration of Response (DoR) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247

  10. Progression Free Survival (PFS) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess the antitumor activity of MEDI7247

  11. Disease Control (DC) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247

  12. Overall Survival (OS) [ Time Frame: From time of informed consent and up to 2 years after last subject in ]
    To assess antitumor activity of MEDI7247



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 101 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmed diagnosis of advanced or metastatic select solid tumors and either progression on or documented intolerance to standard therapies
  2. Age ≥ 18 years at the time of screening.
  3. Written informed consent and any locally required authorization
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  5. At least 1 measurable target lesion by CT or MRI per RECIST Version 1.1 (excluding mCRPC)
  6. Adequate Liver Function: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (upper limit normal), Albumin > 3 g/dL, and serum total bilirubin (TBL) ≤ 1.5 × ULN; (unless bilirubin rise is due to Gilbert's syndrome, hepatic metastases or of non-hepatic origin, in which case TBL ≤ 3 × ULN is allowed)
  7. Creatinine Clearance (CrCL) ≥ 40 mL/min
  8. Adequate Hematopoesis: Absolute Neutrophil Count (ANC) ≥ 1,500/μL, Platelets ≥ 100,000/μL, and Hgb ≥ 9 g/dL unassisted by transfusion or growth factor within 14 days of screening
  9. Provision of archival or fresh tumor tissue at screening
  10. Female patients of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception, and must agree to continue using such precautions for 90 days after the last dose of investigational product.
  11. Nonsterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from 7 days post-screening and for 90 days after receipt of the last dose of investigational product.

Exclusion Criteria:

  1. Active central nervous system (CNS) metastases, unless adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) and prednisolone 10 mg or less for more than 2 weeks prior to enrollment. For SCLC, a brain MRI scan that was conducted ≤ 28 days from Day 1 is required.
  2. Residual toxicity from prior anticancer therapy not resolved to NCI CTCAE v4.03 Grade 1, with the exception of alopecia/vitiligo at the time of first dose of investigational product. For patients previously receiving immunotherapy, toxicities that are unlikely to recover to Grade 1.
  3. Royal Marsden Hospital (RMH) prognostic score 2 and 3 at baseline.
  4. Treatment with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 21 days, or prior palliative radiotherapy within 2 weeks of the first dose of investigational product.

5 Prior treatment with other Pyrrolobenzodiazepine-Antibody Drug Conjugates.

6 History of previous malignancies (except for locally curable cancers) unless a complete remission was achieved at least 3 years prior to study entry AND no additional therapy is required during the study period (except adjuvant hormonal therapy and bisphosphonate).

7. Failure to recover from major surgery or significant traumatic injury within 21 days of first dose of study treatment.

8 History of hepatic sinusoidal obstruction syndrome, also called veno-occlusive disease 9. History of capillary leak syndrome. 10 Blood transfusion within 14 days of study entry except when needed for disease related anemia.

11. New York Heart Association classes III-IV congestive heart failure or serious cardiac arrhythmia requiring treatment, history of myocardial infarction, unstable angina, vascular stent, or coronary artery bypass graft within 6 months of the first dose of investigational product. 12. Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.

13. Current severe active systemic disease including active concurrent malignancy 14. Pregnancy and/or breastfeeding at time of screening 15. Concurrent enrollment in anther clinical study involving an investigational treatment that is not an extension of another MedImmune study with the same investigational product.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03811652


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
United States, North Carolina
Research Site Recruiting
Huntersville, North Carolina, United States, 28078
United States, Tennessee
Research Site Recruiting
Nashville, Tennessee, United States, 37203
Australia
Research Site Not yet recruiting
Heidelberg, Australia, 3084
Canada, CA
Research Site Recruiting
Toronto, CA, Canada, M5G 2M9
France
Research Site Not yet recruiting
Villejuif, France, 94800
Sponsors and Collaborators
MedImmune LLC

Layout table for additonal information
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT03811652     History of Changes
Other Study ID Numbers: D8540C00002
First Posted: January 21, 2019    Key Record Dates
Last Update Posted: April 12, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MedImmune LLC:
Medi7247
non small cell lung cancer
head and neck cancer
small cell lung cancer
colorectal cancer
prostate cancer
pancreatic adenocarcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Prostatic Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial